SCHEMBL2548770

SCHEMBL2548770

COCCN(Cc1ccc(-c2cc3nccc(Oc4ccc(NC(CC(=O)O)C(F)(F)F)cc4F)c3s2)nc1)C(=O)OC(C)(C)C

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MST1R Q04912 12/20 0.63
MET P08581 15/20 0.53
KDR P35968 15/20 0.53
AXL P30530 2/20 0.49
FLT3 P36888 2/20 0.49
NTRK1 P04629 1/20 0.49
KIT P10721 1/20 0.49
NTRK2 Q16620 1/20 0.49
PLK4 O00444 1/20 0.48
MAP4K4 O95819 1/20 0.48
ABL1 P00519 1/20 0.48
LCK P06239 1/20 0.48
FYN P06241 1/20 0.48
LYN P07948 1/20 0.48
HCK P08631 1/20 0.48
PDGFRB P09619 1/20 0.48
BCR P11274 1/20 0.48
SRC P12931 1/20 0.48
ABL2 P42684 1/20 0.48
FRK P42685 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2534930 0.92 MST1R (0.65) MST1RMETKDRAXLFLT3
SCHEMBL1479229 0.88 MST1R (0.70) MST1RMETKDRAXLFLT3
SCHEMBL2535459 0.88 MST1R (0.65) MST1RMETKDRAXLFLT3
SCHEMBL13664120 0.87 MST1R (0.71) MST1RMETKDRAXLFLT3
SCHEMBL1479923 0.86 MST1R (0.70) MST1RMETKDRAXLFLT3
SCHEMBL23118270 0.85 MST1R (0.68) MST1RMETKDRAXLFLT3
SCHEMBL12734272 0.85 MST1R (0.68) MST1RMETKDRAXLFLT3
SCHEMBL16190291 0.85 MET (0.66) MST1RMETKDRAXLFLT3
SCHEMBL12251067 0.85 MET (0.67) MST1RMETKDRAXLFLT3
SCHEMBL12806823 0.85 MST1R (0.68) MST1RMETKDRAXLFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8906852-B2 Inhibitors of protein tyrosine kinase activity METHYLGENE INC. (CA) 2014-12-09 US disclosed
US-20140315801-A1 METHODS OF TREATMENT OF CELL PROLIFERATIVE AND/OR OPHTHALMIC DISEASES, DISORDERS AND CONDITIONS USING INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY METHYLGENE INC (CA) 2014-10-23 US disclosed
US-20110257100-A1 Inhibitors of Protein Tyrosine Kinase Activity METHYLGENE INC. (CA) 2011-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257100-A1 Inhibitors of Protein Tyrosine Kinase Activity ERBB2, ABL1, FLT1 MST1R 150/4885MET 138/4885KDR 5/4885
US-20140315801-A1 METHODS OF TREATMENT OF CELL PROLIFERATIVE AND/OR OPHTHALMIC DISEASES, DISORDERS AND CONDITIONS USING INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY FLT1, KDR, FLT4 MST1R 105/4885MET 49/4885KDR 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.